论文部分内容阅读
１９９３年４月～１９９４年９月间，作者用济南假单胞菌苗注射液（商品名佳代胞，简称ＰＶＩ）胸腔内注射治疗恶性胸膜腔积液，并进行了前瞻性多中心研究。在５０９例接受ＰＶＩ治疗的病人中，肺癌合并胸膜腔积液者３８２例、乳腺癌５４例、淋巴瘤１６例、其它肿瘤５７例，总有效率为８２．７％（４２１／５０９）。在对照组４１例接受顺铂治疗的病人中，肺癌３１例，乳腺癌６例，其它肿瘤４例，总有效率为６１．０％（２５／４１）。ＰＶＩ组的主要不良反应以发热和局部疼痛为主，而顺铂组的主要不良反应则是恶心、呕吐及骨髓抑制。
Between April 1993 and September 1994, the author used intrapleural injection of Jinan Pseudomonas injection (trade name Jiadaiyin, abbreviated as PVI) to treat malignant pleural effusions and conducted a prospective multicenter study. Among 509 patients who received PVI therapy, 382 patients had lung pleural effusion, 54 breast cancers, 16 lymphomas, and 57 other tumors. The total effective rate was 82.7% (421/509). Among the 41 patients who received cisplatin in the control group, 31 were lung cancer, 6 were breast cancer, and 4 were other tumors. The total effective rate was 61.0% (25/41). The main adverse reactions in the PVI group were mainly fever and local pain, while the main adverse reactions in the cisplatin group were nausea, vomiting and bone marrow suppression.